The Fierce Biotech story said "Amgen had some big factors playing in its favor. The experts, like the agency, lean heavily on the side of providing physicians and patients as many treatment choices as possible, particularly in the absence of serious toxicity issues."
CAVATAK has a superior safety profile to T-Vec - it has a better safety profile to all other treatments either approved or undergoing investigation - this is what will bring the big dollars
What a great outcome 22-1. It is now only a matter of time before CAVATAK will be partnered and a large pharma pays for a Phase 3 trial and then licensing. Then there is the combination studies and then there is the IV results- it will be huge
A huge amount of risk has now been taken out of this project - less risk higher share price. The next 12 months are going to be very big.
Very happy shareholder
VLA Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
